Skip NavigationSkip to Content
Return Return to Search Results

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

  1. Author:
    Karzai, Fatima
    VanderWeele, David
    Madan, Ravi A
    Owens, Helen
    Cordes, Lisa M
    Hankin, Amy
    Couvillon, Anna
    Nichols, Erin
    Bilusic, Marijo
    Beshiri, Michael L
    Kelly, Kathleen
    Krishnasamy, Venkatesh
    Lee, Sunmin
    Lee, Min-Jung
    Yuno, Akira
    Trepel, Jane B
    Merino, Maria J
    Dittamore, Ryan
    Marté, Jennifer
    Donahue, Renee N
    Schlom, Jeffrey
    Killian, Keith J
    Meltzer, Paul S
    Steinberg, Seth M
    Gulley, James L
    Lee, Jung-Min
    Dahut, William L

  2. Author Address

    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA., Department of Radiology and Imaging Sciences, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Epic Sciences Inc., San Diego, CA, USA., Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Women 39;s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. dahutw@mail.nih.gov.,
    1. Year: 2018
    2. Date: Dec 04
    3. Epub Date: 2018 12 04
  2. Journal: Journal for immunotherapy of cancer
    1. 6
    2. 1
    3. Pages: 141
  4. Type of Article: Article
  5. Article Number: 141
  6. ISSN: 2051-1426
  1. Abstract:

    Background: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and locally advanced, unresectable stage 3 non-small cell lung cancer. Olaparib, a poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) in select patients with metastatic castration-resistant prostate cancer (mCRPC). Data from other trials suggest there may be improved activity in men with DNA damage repair (DDR) mutations treated with checkpoint inhibitors. This trial evaluated durvalumab and olaparib in patients with mCRPC with and without somatic or germline DDR mutations.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1186/s40425-018-0463-2
  3. PMID: 30514390
  4. View record in Web of Science®
  5. WOS: 000452330800001
  6. PII : 10.1186/s40425-018-0463-2

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel